✦ LIBER ✦

A Double-Blind, Randomized Placebo-Controlled Phase II Study of the Pharmacodynamics, Safety/Tolerability, and Pharmacokinetics of Single Doses of the Motilin Agonist GSK962040, in Patients With Type I Diabetes Mellitus (T1DM) and Gastroparesis

✍ Scribed by Hellström, Per M. ;Tack, Jan F. ;Stephens, Kimberley E. ;Barton, Matthew E. ;Vasist, Lakshmi S. ;Richards, Duncan B. ;Williams, Pauline M. ;Alpers, David H. ;Dukes, George E.

Book ID: 122209600
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 102 KB
Volume: 140
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(11)63366-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND,

737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING ORAL DOSES OF GS-9620 IN HEALTHY SUBJECTS

✍ U. Lopatin; G. Wolfgang; R. Kimberlin; D. Turnas; M. Cornprost; G. Chittick; C. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

70 A Randomized, Double-Blind, Placebo-C

70 A Randomized, Double-Blind, Placebo-Controlled Phase II Study (MOT114479) to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Orally Administered Camicinal, a Motilin Receptor Agonist, in Diabetics With Gastroparesis

✍ Barton, Matthew E.; Otiker, Tal; Johnson, Lakshmi Vasist; Robertson, Darren C.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 218 KB

Pharmacokinetic, pharmacodynamic, and to

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

✍ Paul Covington; Ronald Christopher; Michael Davenport; Penny Fleck; Qais A. Mekk 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 253 KB

(210) Results from a phase I, double-bli

(210) Results from a phase I, double-blind, randomized, placebo-controlled, multiple-dose study evaluating the safety, tolerability, and pharmacokinetics of oral doses of NKTR-118

✍ D. Sahner; H. van Paaschen; A. Marcantonio; M. Eldon 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Pharmacokinetics, pharmacodynamics, and

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose—block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study

✍ Kyoung Soo Lim; Jung-Ryul Kim; Yun-Jung Choi; Kwang-Hee Shin; Kyu-Pyo Kim; Jang- 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 169 KB

A multicenter, randomized, placebo-contr

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes

✍ E. J. Rhee; W. Y. Lee; K. H. Yoon; S. J. Yoo; I. K. Lee; S. H. Baik; Y. K. Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 531 KB